| Reduced Risk Status: |
|
| IPM Compatibility: |
PER REQUESTER, A VERY GOOD FIT; INSECTICIDES FOR USE IN GREENHOUSE, ESPECIALLY WITH A NEW IRAC GROUP ARE KEY TO MANAGING INSECT PESTS; TSSM MANAGEMENT IS A MAJOR CHALLENGE; THIS INSECTICIDE ALSO HAS SOME COLEOPTERA ACTIVITY; UNKNOWN: : SOR; VERY GOOD FIT: SEE PREVIOUS COMMENT.: SOR;
|
| Reasons for need: |
TSSM ARE A CONSISTENT PROBLEM IN GREENHOUSE CUCUMBERS; ROTATION PRODUCTS ARE NEEDED
|
| Requesting State(s): |
CA:Sfetcu, D ; FL:Bledsoe, M* ; NY:Tift, K ; OH:Tift, K ; VA:Lopez, L ;
|
| PCR Use Pattern: |
ISOCYCLOSERAM AT A RATE OF 296 G AI/HA AS A FOLIAR APPLIC, WITH 2-3 APPLIC. RE-TREATMENT INTERVAL 7-14 DAYS, 0-1 DAY PHI; FOLIAR APPLIC AT LABELED RATE; NO KNOWN LIMITATIONS:01/22; RATE APPEARS TO BE INCORRECT; FOLLOW DFU'S LISTED BELOW UNDER E/CS DATA REQUIREMENTS:03/22
|
| EPA Default Residue Trials: |
ANY 4 TRIALS
|
| IR-4 Residue Trial Plan: |
ANY 4 TRIALS
|
| Residue Protocol Use Pattern: |
CANADA IS SPONSOR AND STUDY DIRECTOR AND IS CONDUCTING A 5-TRIAL GH STUDY; USE THE SC200 FORMULATION OF ISOCYCLOSERAM (1.7 LB AI/GAL); MAKE 2 FOLIAR APPLIC OF 0.053 LB AI/A IN 55-270 GPA, 7-DAY INTERVAL, 1-DAY PHI; ALL APPLIC SHALL INCLUDE A LABELED RATE OF A NON-IONIC SURFACTANT, BUT NOT TO EXCEED 0.01%
|
| Efficacy/Crop Safety (E/CS) Data Required: |
DFUS - 60 G AI/HA, 3 FOLIAR APPLIC, 7-DAY RTI, 3-DAY PHI:03/22
|
| E/CS Research Comments: |
Canada conducting Efficacy on thrips but are trying to evaluate TSSM also: JPB, 10/23; No performance/efficacy data is needed in the US:04/24/sb
|
| Label Use Pattern Submitted To EPA: |
|
| EPA PIF Status: |
Blue 08/22; Blue: 08/23, 12/23
|
| EPA Status: |
|
| EPA PRIA Date: |
|
| MRID: |
|
| Comments: |
PMC PRIORITY; Changed to an A at NRPM and will be a joint project with PMC and they are the SD: Canada conducting Efficacy on thrips but are trying to evaluate TSSM also: JPB, 10/23; EPA Blue 12/23; Canadian Study# AAFC23-006R:01/24/sb; Researchable, Residue & E/CS Data Needed has been updated to Complete with On-Going Trials:03/24/sb; No performance/efficacy data is needed in the US:04/24/sb; this was a 2024 IR-4 study, so the trial & lab id #'s used in the IR-4 database are 2024:11/24/sb;
|
| International Status: |
|
| Archive Location: |
|
| QA Archive: |
|